Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Receivables - Net: 2020-2023

Historic Receivables - Net for Rocket Pharmaceuticals (RCKT) over the last 1 years, with Dec 2023 value amounting to $50,000.

  • Rocket Pharmaceuticals' Receivables - Net was N/A to $50,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $50,000, marking a year-over-year change of. This contributed to the annual value of $50,000 for FY2023, which is N/A change from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Receivables - Net of $50,000 as of Q4 2023, which was down 94.44% from $900,000 recorded in Q1 2022.
  • Rocket Pharmaceuticals' 5-year Receivables - Net high stood at $1.6 million for Q2 2020, and its period low was $50,000 during Q4 2023.
  • Moreover, its 3-year median value for Receivables - Net was $950,000 (2021), whereas its average is $737,500.
  • Data for Rocket Pharmaceuticals' Receivables - Net shows a maximum YoY tumbled of 37.50% (in 2021) over the last 5 years.
  • Rocket Pharmaceuticals' Receivables - Net (Quarterly) stood at $1.1 million in 2020, then plummeted by 37.50% to $1.0 million in 2021, then dropped by 10.00% to $900,000 in 2022, then reached $50,000 in 2023.
  • Its Receivables - Net was $50,000 in Q4 2023, compared to $900,000 in Q1 2022 and $1.0 million in Q2 2021.